EUVIMEDOpdag EUVIMED
Crossref

Serial sensitive molecular detection of JAK2 V617F is predictive of relapse after allogeneic stem cell transplantation in patients with myelofibrosis

Rithin Nedumannil iD, Tal Karmi, Piers Blombery iD, Jeff Szer iD, David S Ritchie iD, Lynette C Y Chee

British Journal of Haematology · 2025

DOI: 10.1111/bjh.20003 ↗

At a glance

Journal article in British Journal of Haematology, 2025. Written by Rithin Nedumannil and 5 co-authors. Institution: Department of Clinical Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Victoria, Australia. Major MEDLINE topics: Janus Kinase 2, Primary Myelofibrosis, Hematopoietic Stem Cell Transplantation. Cited 3 times so far (Crossref); 10 references. Funded by: The Wilson Centre for Blood Cancer Genomics, Snowdome Foundation.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Relapse after allogeneic stem cell transplantation (alloSCT) represents a frequent complication in patients with myelofibrosis (MF). This retrospective study analysed 38 patients with JAK2 ‐mutated MF who underwent alloSCT. Serial sensitive molecular assessments at regular intervals of JAK2 V617F revealed that a ≥2‐fold increase in JAK2 variant allele frequency (VAF) at days +100 and +180 post‐alloSCT was highly predictive of eventual morphological relapse. The integration of JAK2 VAF monitoring with chimerism analysis into post‐alloSCT care represents a novel strategy for early detection of MF relapse, which may enable timely interventions and improve outcomes in such high‐risk patients.

Subjects

MeSH terms (MEDLINE)

Janus Kinase 2Primary MyelofibrosisHematopoietic Stem Cell TransplantationHumansMaleMiddle AgedFemaleRetrospective StudiesRecurrenceTransplantation, HomologousAdultAgedGene FrequencyMutation

Author keywords

molecular pathologymyelofibrosisrelapsestem cell transplantation

Substances

Janus Kinase 2JAK2 protein, human

Authors and institutions

  • Department of Clinical Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, Victoria, Australia.
  • Department of Pathology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
  • Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia.
  • Department of Medicine, The University of Melbourne, Parkville, Victoria, Australia.

ORCID profiles: Rithin Nedumannil, Piers Blombery, Jeff Szer, David S Ritchie

Funding

  • The Wilson Centre for Blood Cancer Genomics
  • Snowdome Foundation

Cite

APA

Nedumannil, R., Karmi, T., Blombery, P., Szer, J., Ritchie, D. S., & Chee, L. C. Y. (2025). Serial sensitive molecular detection of JAK2 V617F is predictive of relapse after allogeneic stem cell transplantation in patients with myelofibrosis. British Journal of Haematology. https://doi.org/10.1111/bjh.20003

Vancouver

Nedumannil R, Karmi T, Blombery P, Szer J, Ritchie DS, Chee LCY. Serial sensitive molecular detection of JAK2 V617F is predictive of relapse after allogeneic stem cell transplantation in patients with myelofibrosis. British Journal of Haematology. 2025. doi:10.1111/bjh.20003

BibTeX
@article{Nedumannil2025,
  author = {Nedumannil, Rithin and Karmi, Tal and Blombery, Piers and Szer, Jeff and Ritchie, David S and Chee, Lynette C Y},
  title = {Serial sensitive molecular detection of JAK2 V617F is predictive of relapse after allogeneic stem cell transplantation in patients with myelofibrosis},
  journal = {British Journal of Haematology},
  year = {2025},
  doi = {10.1111/bjh.20003}
}
Start for free →